Sandrine Vendeville

VP, Head of Medicinal Chemistry and Co-founder

A highly accomplished medicinal chemist, she brings over 20 years of experience in drug discovery and development in oncology and virology. Prior to Onco3R, Sandrine was Senior Director of Medicinal Chemistry at Galapagos, where she led the design and implementation of the medicinal chemistry strategy for the oncology small molecule franchise. Previously, Sandrine held senior scientific roles at Aligos Therapeutics, Janssen Pharmaceutica (J&J Innovative Medicine), and Tibotec. Over the course of her career, she has played a pivotal role in the design and discovery of multiple drug candidates, including FDA-approved therapies darunavir and simeprevir, as well as late-stage assets such as rilematovir, JNJ647055, and ALG184. Sandrine holds a PhD in Organic and Medicinal Chemistry from the University of Lille, a PharmD from UC Louvain, and a Master’s degree in Drug Design from the University of Pharmacy of Lille. She is widely recognized for her strategic leadership in medicinal chemistry and her ability to translate molecular innovation into impactful therapies.